Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for ...

U.S. telehealth platform looks to take advantage of Ozempic patent expiring in January, while four manufacturers filed for ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Asking people with type 2 diabetes their language and care preferences is vital to optimise outcomes globally, says Heather Koga As the US writer Ingrid Bengis said, “Words are a form of action, ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announced that human study GLP-1-H25-5 which ...

A recent analysis of adverse drug reactions by Indian Pharmacopoeia Commission revealed that combinations of beta-blockers ...

More than 6,700 University of Nebraska–Lincoln students have been named to the Deans’ List for the spring semester of the ...